MDxHealth to Present First Quarter 2023 Financial Results on May 15

NEWS RELEASE 1 MAY 2023, 4PM ET / 22:00 CET

           MDxHealth to Present First Quarter 2023 Financial Results on May 15

Company to Host Conference Call with Live Q&A, May 15, 2023 at 4:30pm ET/ 22:30 CET

IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023.

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About MDxHealthmdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Attachment

• MDXH 1Q23 Earnings Save the Date

You May Also Be Interested In

• HAIRCUTS FOR HEROES EVENT PROVIDES FREE HAIRCUTS FOR VETERANS, FIRST RESPONDERS, AND ACTIVE-DUTY SERVICE MEMBERS
• New Clinical Review Highlights Alpha-Stim® in Expanding Neuromodulation Landscape
• Brookfield Office Properties Announces Reset Dividend Rates and Conversion Privileges on Its Class AAA Series R Preference Shares